Exploiting biological diversity and genomic aberrations in chronic lymphocytic leukemia

Leukemia and Lymphoma

Volumn 53, Issue 6, 2012, Pages 1023-1031

  Seiffert, Martina ^a   Dietrich, Sascha ^b   Jethwa, Alexander ^a   Glimm, Hanno ^a   Lichter, Peter ^a   Zenz, Thorsten ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Chronic lymphocytic leukemia; Cytogenetics; Drug resistance; Lymphocytes; Microenvironment; Molecular genetics

Indexed keywords

ATM PROTEIN; MICRORNA; MICRORNA 15A; MICRORNA 16 1; MYELOID DIFFERENTIATION FACTOR 88; NOTCH1 RECEPTOR; PROTEIN P53; UNCLASSIFIED DRUG;

CANCER PROGNOSIS; CANCER RISK; CHROMOSOME 11Q; CHROMOSOME 13Q; CHROMOSOME 17P; CHROMOSOME DELETION; CHROMOTRIPSIS; CHRONIC LYMPHATIC LEUKEMIA; GENE MUTATION; GENE SEQUENCE; GENOMICS; HUMAN; IMMUNOGLOBULIN HEAVY CHAIN GENE; LEUKEMIA CELL; MUTATIONAL ANALYSIS; NONHUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; TRISOMY 12; TUMOR MICROENVIRONMENT;

ANIMALS; BIODIVERSITY; CHROMOSOME ABERRATIONS; GENES, IMMUNOGLOBULIN HEAVY CHAIN; GENETIC HETEROGENEITY; GENOME, HUMAN; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MEDICAL ONCOLOGY; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; TUMOR MICROENVIRONMENT;

EID: 84861377739     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.631638     Document Type: Review

References (99)

1. Messmer BT, Messmer D, Allen SL et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest 2005;115:755-764. (Pubitemid 40322252)
2. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005;352:804-815.
3. Caligaris-Cappio F, Ghia P. Novel insights in chronic lymphocytic leukemia: are we getting closer to understanding the pathogenesis of the disease? J Clin Oncol 2008;26:4497-4503.
4. Zenz T, Mertens D, Küppers R, et al. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer 2010;10:37-50.
5. Zenz T, Mertens D, Stilgenbauer S. Biological diversity and riskadapted treatment of chronic lymphocytic leukemia. Haematologica 2010;95:1441-1443.
6. Hamblin TJ, Davis Z, Gardiner A, et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999;94:1848-1854. (Pubitemid 29430400)
7. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999;94:1840-1847. (Pubitemid 29430399)
8. Tobin G, Th unberg U, Karlsson K, et al. Subsets with restricted immunoglobulin gene rearrangement features indicate a role for antigen selection in the development of chronic lymphocytic leukemia. Blood 2004;104:2879-2885. (Pubitemid 39434975)
9. Stamatopoulos K, Belessi C, Moreno C, et al. Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: pathogenetic implications and clinical correlations. Blood 2007;109:259-270. (Pubitemid 46070124)
10. Tobin G, Th unberg U, Johnson A, et al. Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia. Blood 2002;99:2262-2264. (Pubitemid 34525519)
11. Ghia EM, Jain S, Widhopf GF 2nd, et al. Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and refl ects antigen-driven, post-germinal center leukemogenic selection. Blood 2008;111:5101-5108.
12. Lagneaux L, Delforge A, Bron D, et al. Chronic lymphocytic leukemic B cells but not normal B cells are rescued from apoptosis by contact with normal bone marrow stromal cells. Blood 1998;91:2387-2396.
13. Burger JA, Tsukada N, Burger M, et al. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood 2000;96:2655-2663.
14. Pedersen IM, Kitada S, Leoni LM, et al. Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1. Blood 2002;100:1795-1801. (Pubitemid 34925159)
15. Panayiotidis P, Jones D, Ganeshaguru K, et al. Human bone marrow stromal cells prevent apoptosis and support the survival of chronic lymphocytic leukaemia cells in vitro. Br J Haematol 1996;92:97-103. (Pubitemid 26018774)
16. Kurtova AV, Balakrishnan K, Chen R, et al. Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood 2009;114:4441-4450.
17. Seiff ert M, Stilgenbauer S, Döhner H, et al. Efficient nucleofection of primary human B cells and B-CLL cells induces apoptosis, which depends on the microenvironment and on the structure of transfected nucleic acids. Leukemia 2007;21:1977-1983. (Pubitemid 47299973)
18. Seiff ert M, Schulz A, Ohl S, et al. Soluble CD14 is a novel monocytederived survival factor for chronic lymphocytic leukemia cells, which is induced by CLL cells in vitro and present at abnormally high levels in vivo. Blood 2010;116:4223-4230.
19. Ghia P, Circosta P, Scielzo C, et al. Diff erential Effects on CLL cell survival exerted by diff erent microenvironmental elements. Curr Top Microbiol Immunol 2005;294:135-145. (Pubitemid 41491253)
20. Ghia P, Strola G, Granziero L, et al. Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4 + , CD40L + T cells by producing CCL22. Eur J Immunol 2002;32:1403-1413. (Pubitemid 34546268)
21. Burger JA, Quiroga MP, Hartmann E, et al. High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation. Blood 2009;113:3050-3058.
22. Mikaelsson E, Danesh-Manesh AH, L ü ppert A, et al. Fibromodulin, an extracellular matrix protein: characterization of its unique gene and protein expression in B-cell chronic lymphocytic leukemia and mantle cell lymphoma. Blood 2005;105:4828-4835. (Pubitemid 40807310)
23. Ghosh AK, Secreto CR, Knox TR, et al. Circulating microvesicles in B-cell chronic lymphocytic leukemia can stimulate marrow stromal cells: implications for disease progression. Blood 2010;115:1755-1764.
24. Woessner S, Asensio A, Florensa L, et al. Expression of lymphocyte function-associated antigen (LFA)-1 in B-cell chronic lymphocytic leukemia. Leuk Lymphoma 1994;13:457-461. (Pubitemid 24158966)
25. Hartmann TN, Grabovsky V, Wang W, et al. Circulating B-cell chronic lymphocytic leukemia cells display impaired migration to lymph nodes and bone marrow. Cancer Res 2009;69:3121-3130.
26. Gu B, Dao L-P, Wiley J. Impaired transendothelial migration of B-CLL lymphocytes: a defect linked to low L-selectin expression. Leuk Lymphoma 2001;42:5-12. (Pubitemid 32700917)
27. Till KJ, Zuzel M, Cawley JC. The role of hyaluronan and interleukin 8 in the migration of chronic lymphocytic leukemia cells within lymphoreticular tissues. Cancer Res 1999;59:4419-4426. (Pubitemid 29418763)
28. Giannopoulos K, Mertens D, Buhler A, et al. The candidate immunotherapeutical target, the receptor for hyaluronic acid-mediated motility, is associated with proliferation and shows prognostic value in B-cell chronic lymphocytic leukemia. Leukemia 2009;23:519-527.
29. Buggins AGS, Levi A, Gohil S, et al. Evidence for a macromolecular complex in poor prognosis CLL that contains CD38, CD49d, CD44 and MMP-9. Br J Haematol 2011;154:216-222.
30. Redondo-Muñ o z J, Ugarte-Berzal E, Garcí a -Marco J, et al. Alpha4beta1 integrin and 190-kDa CD44v constitute a cell surface docking complex for gelatinase B/MMP-9 in chronic leukemic but not in normal B cells. Blood 2008;112:169-178.
31. Redondo-Muñ o z J, Ugarte-Berzal E, Terol MJ, et al. Matrix metalloproteinase-9 promotes chronic lymphocytic leukemia B cell survival through its hemopexin domain. Cancer Cell 2010;17:160-172.
32. de Martel C, Franceschi S. Infections and cancer: established associations and new hypotheses. Crit Rev Oncol Hematol 2009;70: 183-194.
33. Sparmann A, Bar-Sagi D. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 2004;6:447-458. (Pubitemid 39469981)
34. Soucek L, Lawlor ER, Soto D, et al. Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat Med 2007;13:1211-1218. (Pubitemid 47530639)
35. Sodir NM, Swigart LB, Karnezis AN, et al. Endogenous Myc maintains the tumor microenvironment. Genes Dev 2011;25:907-916.
36. Bhattacharya N, Diener S, Idler IS, et al. Non-malignant B cells and chronic lymphocytic leukemia cells induce a pro-survival phenotype in CD14( + ) cells from peripheral blood. Leukemia 2011;25:722-726.
37. Ramsay AG, Johnson AJ, Lee AM, et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest 2008;118:2427-2437. (Pubitemid 351949771)
38. Ding W, Nowakowski GS, Knox TR, et al. Bi-directional activation between mesenchymal stem cells and CLL B-cells: implication for CLL disease progression. Br J Haematol 2009;147:471-483.
39. Klein U, Tu Y, Stolovitzky GA, et al. Gene expression profi ling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med 2001;194:1625-1638. (Pubitemid 33126813)
40. Deaglio S, Capobianco A, Bergui L, et al. CD38 is a signaling molecule in B-cell chronic lymphocytic leukemia cells. Blood 2003;102:2146-2155. (Pubitemid 37122392)
41. Gordon MS, Kato RM, Lansigan F, et al. Aberrant B cell receptor signaling from B29 (Igbeta, CD79b) gene mutations of chronic lymphocytic leukemia B cells. Proc Natl Acad Sci USA 2000;97:5504-5509. (Pubitemid 30313748)
42. Chen L, Widhopf G, Huynh L, et al. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2002;100:4609-4614. (Pubitemid 35429705)
43. Contri A, Brunati AM, Trentin L, et al. Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis. J Clin Invest 2005;115:369-378. (Pubitemid 40385478)
44. Semichon M, Merle-Beral H, Lang V, et al. Normal Syk protein level but abnormal tyrosine phosphorylation in B-CLL cells. Leukemia 1997;11:1921-1928. (Pubitemid 27485139)
45. Herman SEM, Gordon AL, Hertlein E, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 2011;117:6287-6296.
46. Quiroga MP, Balakrishnan K, Kurtova AV, et al. B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specifi c targeting with a novel spleen tyrosine kinase inhibitor, R406. Blood 2009;114:1029-1037.
47. Friedberg JW, Sharman J, Sweetenham J, et al. Inhibition of Syk with fostamatinib disodium has signifi cant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010;115:2578-2585.
48. Amrein PC, Attar EC, Takvorian T, et al. Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res 2011;17:2977-2986.
49. Schattner EJ. CD40 ligand in CLL pathogenesis and therapy. Leuk Lymphoma 2000;37:461-472. (Pubitemid 30219055)
50. Burger JA. Chemokines and chemokine receptors in chronic lymphocytic leukemia (CLL): from understanding the basics towards therapeutic targeting. Semin Cancer Biol 2010;20:424-430.
51. Muzio M, Bertilaccio MTS, Simonetti G, et al. The role of Tolllike receptors in chronic B cell malignancies. Leuk Lymphoma 2009;50:1573-1580.
52. Hewamana S, Alghazal S, Lin TT, et al. The NF-kappaB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target. Blood 2008;111:4681-4689.
53. Kitada S, Zapata JM, Andreeff M, et al. Bryostatin and CD40- ligand enhance apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukaemia. Br J Haematol 1999;106:995-1004. (Pubitemid 29463014)
54. Romano MF, Lamberti A, Tassone P, et al. Triggering of CD40 antigen inhibits fl udarabine-induced apoptosis in B chronic lymphocytic leukemia cells. Blood 1998;92:990-995. (Pubitemid 28355483)
55. Kater AP, Evers LM, Remmerswaal EBM, et al. CD40 stimulation of B-cell chronic lymphocytic leukaemia cells enhances the antiapoptotic profi le, but also Bid expression and cells remain susceptible to autologous cytotoxic T-lymphocyte attack. Br J Haematol 2004;127:404-415. (Pubitemid 39536592)
56. Pepper C, Lin TT, Pratt G, et al. Mcl-1 expression has in vitro and in vivo signifi cance in chronic lymphocytic leukemia and is associated with other poor prognostic markers. Blood 2008;112:3807-3817.
57. Vogler M, Butterworth M, Majid A, et al. Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. Blood 2009;113:4403-4413.
58. Herishanu Y, Perez-Galan P, Liu D, et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 2011;117:563-574.
59. Schulz A, Toedt G, Zenz T, et al. Infl ammatory cytokines and signaling pathways are associated with survival of primary chronic lymphocytic leukemia cells in vitro: a dominant role of CCL2. Haematologica 2011;96:408-416.
60. Muzio M, Scielzo C, Bertilaccio M, et al. Expression and function of toll like receptors in chronic lymphocytic leukaemia cells. Br J Haematol 2009;144:507-516.
61. Porakishvili N, Kulikova N, Jewell AP, et al. Diff erential expression of CD180 and IgM by B-cell chronic lymphocytic leukaemia cells using mutated and unmutated immunoglobulin VH genes. Br J Haematol 2005;131:313-319. (Pubitemid 43899663)
62. Jahrsdorfer B, M ü hlenhoff L, Blackwell SE, et al. B-cell lymphomas diff er in their responsiveness to CpG oligodeoxynucleotides. Clin Cancer Res 2005;11:1490-1499. (Pubitemid 40315231)
63. Longo PG, Laurenti L, Gobessi S, et al. The Akt signaling pathway determines the diff erent proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease. Leukemia 2006;21:110-120. (Pubitemid 44921842)
64. Spaner DE, Shi Y, White D, et al. Immunomodulatory Effects of Toll-like receptor-7 activation on chronic lymphocytic leukemia cells. Leukemia 2005;20:286-295.
65. Puente XS, Pinyol M, Quesada V, et al. Whole-genome sequencing identifi es recurrent mutations in chronic lymphocytic leukaemia. Nature 2011;475:101-105.
66. Spaner DE, Shi Y, White D, et al. A phase I/II trial of TLR-7 agonist immunotherapy in chronic lymphocytic leukemia. Leukemia 2009;24:222-226.
67. Friedberg JW, Kelly JL, Neuberg D, et al. Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma. Br J Haematol 2009;146:282-291.
68. Geller M, Cooley S, Argenta P, et al. Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers. Cancer Immunol Immunother 2010;59:1877-1884.
69. Huang B, Zhao J, Unkeless JC, et al. TLR signaling by tumor and immune cells: a double-edged sword. Oncogene 2008;27:218-224.
70. Yu L, Chen S. Toll-like receptors expressed in tumor cells: targets for therapy. Cancer Immunol Immunother 2008;57:1271-1278.
71. Giannopoulos K, Mertens D, Buhler A, et al. The candidate immunotherapeutical target, the receptor for hyaluronic acid-mediated motility, is associated with proliferation and shows prognostic value in B-cell chronic lymphocytic leukemia. Leukemia 2008;23:519-527.
72. Vlad A, Deglesne PA, Letestu R, et al. Down-regulation of CXCR4 and CD62L in chronic lymphocytic leukemia cells is triggered by B-cell receptor ligation and associated with progressive disease. Cancer Res 2009;69:6387-6395.
73. Sivina M, Hartmann E, Kipps TJ, et al. CCL3 (MIP-1alpha) plasma levels and the risk for disease progression in chronic lymphocytic leukemia. Blood 2011;117:1662-1669.
74. Stilgenbauer S, Zenz T. Understanding and managing ultra highrisk chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2010:481-488.
75. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fl udarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010;376:1164-1174.
76. Zenz T, Vollmer D, Trbusek M, et al. TP53 mutation profi le in chronic lymphocytic leukemia: evidence for a disease specifi c profi le from a comprehensive analysis of 268 mutations. Leukemia 2010;24:2072-2079.
77. Trbusek M, Smardova J, Malcikova J, et al. Missense mutations located in structural p53 DNA-binding motifs are associated with extremely poor survival in chronic lymphocytic leukemia. J Clin Oncol 2011;29:2703-2708.
78. Zenz T, Frohling S, Mertens D, et al. Moving from prognostic to predictive factors in chronic lymphocytic leukaemia (CLL). Best Pract Res Clin Haematol 2010;23:71-84.
79. Austen B, Skowronska A, Baker C, et al. Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion. J Clin Oncol 2007;25:5448-5457. (Pubitemid 350232222)
80. Dickinson JD, Gilmore J, Iqbal J, et al. 11q22.3 deletion in B-chronic lymphocytic leukemia is specifi cally associated with bulky lymphadenopathy and ZAP-70 expression but not reduced expression of adhesion/cell surface receptor molecules. Leuk Lymphoma 2006;47:231-244. (Pubitemid 43084561)
81. Mayr C, Speicher MR, Kofl er DM, et al. Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia. Blood 2006;107:742-751. (Pubitemid 43076401)
82. Tam CS, Otero-Palacios J, Abruzzo LV, et al. Chronic lymphocytic leukaemia CD20 expression is dependent on the genetic subtype: a study of quantitative fl ow cytometry and fl uorescent in-situ hybridization in 510 patients. Br J Haematol 2008;141:36-40. (Pubitemid 351347535)
83. Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002;99:15524-15529. (Pubitemid 35403967)
84. Cimmino A, Calin GA, Fabbri M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 2005;102:13944-13949. (Pubitemid 41377683)
85. Lagos-Quintana M, Rauhut R, Lendeckel W, et al. Identifi cation of novel genes coding for small expressed RNAs. Science 2001;294:853-858. (Pubitemid 33032103)
86. Stephens PJ, Greenman CD, Fu B, et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 2011;144:27-40.
87. Di Ianni M, Baldoni S, Rosati E, et al. A new genetic lesion in B-CLL: a NOTCH1 PEST domain mutation. Br J Haematol. 2009;146: 689-91.
88. Weng AP, Ferrando AA, Lee W, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004;306:269-271. (Pubitemid 39336870)
89. Sportoletti P, Baldoni S, Cavalli L, et al. NOTCH1 PEST domain mutation is an adverse prognostic factor in B-CLL. Br J Haematol 2010;151:404-406.
90. Fabbri G, Rasi S, Rossi D, et al. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med 2011;208:1389-1401.
91. Kawagoe T, Sato S, Matsushita K, et al. Sequential control of Tolllike receptor-dependent responses by IRAK1 and IRAK2. Nat Immunol 2008;9:684-691. (Pubitemid 351712639)
92. Ngo VN, Young RM, Schmitz R, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 2011;470:115-119.
93. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111:5446-5456.
94. Dreger P, Dohner H, Ritgen M, et al. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood 2010;116:2438-2447.
95. Dreger P. Allotransplantation for chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2009:602-609.
96. Dreger P, Corradini P, Kimby E, et al. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia 2007;21:12-17. (Pubitemid 44921829)
97. Austen B, Powell JE, Alvi A, et al. Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL. Blood 2005;106:3175-3182. (Pubitemid 41565916)
98. Schaffner C, Stilgenbauer S, Rappold GA, et al. Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia. Blood 1999;94:748-753. (Pubitemid 29323889)
99. Stankovic T, Weber P, Stewart G, et al. Inactivation of ataxia telangiectasia mutated gene in B-cell chronic lymphocytic leukaemia. Lancet 1999;353:26-29. (Pubitemid 29037699)